Unsolved problems and future perspectives of hepatitis B virus vaccination  

作　　者：Kazuto Tajiri Yukihiro Shimizu 

机构地区：[1]Department of Gastroenterology, Toyama Univer-sity Hospital [2]Gastroenterology Center, Nanto Municipal Hospital

出　　处：《World Journal of Gastroenterology》2015年第23期7074-7083,共10页世界胃肠病学杂志（英文版）

摘　　要：Hepatitis B virus(HBV) infection is still a serious worldwide problem, and vaccination is the most effective strategy for primary prevention of the infection. Although universal vaccination may be required for total eradication, several countries, including Japan, have not yet adopted universal vaccination programs. Some individuals are non-responders to HBV vaccine and several mechanisms responsible for their poor response have been proposed. To overcome non-response, third generation vaccines with pre-S proteins have been developed. These vaccines have shown better antiHBs responses and may also be effective in preventing infection by HBV with S mutant. Improvement of vaccine efficacy by intradermal administration, or coadministration with cytokines or adjuvants, may also be effective in non-responders. The necessity, timing and method of booster vaccination in responders with decreased anti-HBs responses, and effective vaccination against S-mutant HBV, are issues requiring resolution in the global prevention of HBV infection.Hepatitis B virus(HBV) infection is still a serious worldwide problem, and vaccination is the most effective strategy for primary prevention of the infection. Although universal vaccination may be required for total eradication, several countries, including Japan, have not yet adopted universal vaccination programs. Some individuals are non-responders to HBV vaccine and several mechanisms responsible for their poor response have been proposed. To overcome non-response, third generation vaccines with pre-S proteins have been developed. These vaccines have shown better antiHBs responses and may also be effective in preventing infection by HBV with S mutant. Improvement of vaccine efficacy by intradermal administration, or coadministration with cytokines or adjuvants, may also be effective in non-responders. The necessity, timing and method of booster vaccination in responders with decreased anti-HBs responses, and effective vaccination against S-mutant HBV, are issues requiring resolution in the global prevention of HBV infection.

关 键 词：ESCAPE MUTANT IMMUNOLOGY Hepatitis Bvirus VACCINATION NON-RESPONDER Universal VACCINATION 

分 类 号：R392[医药卫生—免疫学] R512.62[医药卫生—基础医学]